Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Perspective Therapeutics Inc CATX

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.


NYSEAM:CATX - Post by User

Post by kingposton May 23, 2015 4:10pm
196 Views
Post# 23757699

Impressive 5 yr peer study for long cancer out last week

Impressive 5 yr peer study for long cancer out last weekThe results were almost as good as could be hoped for... IMO their fully FDA approved product should be adopted as the standard of care for lung cancer operations, with these latest reults...utilizing cesium 1-131 seeds which have a 1/2 life of 9 days and are a local treatment of radiation implanted or seeded in the bed of the tumor --- eliminating the need for chemo....
results were:
-100 % survive over 5 yr...
-recomended by the study for major lung cancer operations as the standard...

Buying opportunity now IMO created by recent Hedge Fund/major pharma/pharma blogger stock manipulation, where they bashed stock down to cover a large mistaken short position and gain a block of long stock at low prices...... Yahoo message board for ISR (Isoray) has some very smart poster now explaining what has happed and what to expect... You have to be careful who you listen to there however..

Bullboard Posts